Tyra biosciences reports interim clinical proof-of-concept data for tyra-300, an investigational oral fgfr3-selective inhibitor, in phase 1/2 surf301 study in patients with metastatic urothelial cancer (muc)

- encouraging preliminary anti-tumor activity observed in heavily pre-treated population - - at ≥ 90 mg qd, 6 out of 11 (54.5%) patients with fgfr3+ muc achieved a confirmed partial response (pr), with 100% disease control rate and sustained duration of activity - - positive safety results across all qd doses, with infrequent fgfr2/fgfr1-associated toxicities - - conference call scheduled for october 25th, 2024, at 8am edt - carlsbad, calif. , oct. 24, 2024 /prnewswire/ -- tyra biosciences, inc. (nasdaq: tyra), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in fibroblast growth factor receptor (fgfr) biology, announced today clinical proof-of-concept data for tyra-300 in patients with metastatic urothelial (muc) cancer from its ongoing surf301 phase 1/2 study.
TYRA Ratings Summary
TYRA Quant Ranking